Mounjaro vs Ozempic: Head-to-Head Clinical Comparison

Until recently, comparing Mounjaro (tirzepatide) and Ozempic (semaglutide) meant looking at separate clinical trials with different patient populations and study designs. That changed with the SURMOUNT-5 trial — the first direct, head-to-head comparison of these two blockbuster medications, published in the New England Journal of Medicine.

This guide summarizes the evidence from SURMOUNT-5 and other major trials so you can make an informed decision. No marketing. Just published data.

The head-to-head trial: SURMOUNT-5

SURMOUNT-5 was an open-label, controlled trial that enrolled 751 adults with obesity (BMI ≥30) who did not have type 2 diabetes. Participants were randomly assigned 1:1 to receive either tirzepatide (maximum tolerated dose of 10 or 15 mg) or semaglutide (maximum tolerated dose of 1.7 or 2.4 mg) weekly for 72 weeks.

The result was clear: tirzepatide produced significantly more weight loss. At week 72, participants on tirzepatide lost an average of 20.2% of their body weight, compared to 13.7% for semaglutide — a difference of 6.5 percentage points. For a 220-pound person, that's roughly 44 pounds lost with tirzepatide vs 30 pounds with semaglutide.

Key differences explained

Important note on brand names: "Mounjaro" and "Ozempic" are technically the diabetes brands. Their weight-loss equivalents are "Zepbound" (tirzepatide) and "Wegovy" (semaglutide). However, people commonly use Mounjaro and Ozempic interchangeably, so we use those names in this article while specifying the actual active ingredient where it matters.

Weight loss: detailed comparison

Tirzepatide clinical results (SURMOUNT program)

The SURMOUNT-1 trial — the pivotal trial for tirzepatide in obesity — tested three doses in 2,539 adults without diabetes over 72 weeks:

• 5 mg dose: 16.0% average weight loss (35 lbs)
• 10 mg dose: 21.4% average weight loss (49 lbs)
• 15 mg dose: 22.5% average weight loss (52 lbs)
• Placebo: 2.4% (5 lbs)

At the 15 mg dose, 57% of participants lost 20% or more of their body weight — an outcome previously achievable only through bariatric surgery.

Semaglutide clinical results (STEP program)

The STEP trial program tested semaglutide 2.4 mg across multiple populations:

• STEP 1 (without diabetes): 14.9% weight loss at 68 weeks (n=1,961)
• STEP 2 (with type 2 diabetes): 9.6% weight loss at 68 weeks (n=1,210)
• STEP 5 (2-year follow-up): 15.2% weight loss sustained at 104 weeks (n=304)

Between 69-79% of participants across STEP trials achieved at least 10% weight loss with semaglutide 2.4 mg.

Body composition: not just weight, but fat

A key concern with weight loss drugs is whether you lose fat or muscle. Analysis of SURMOUNT-1 body composition data showed that of the weight lost with tirzepatide, approximately 75% was fat mass and 25% was lean mass — a ratio consistent with what's seen in healthy weight loss through diet and exercise.

Why tirzepatide produces more weight loss

The answer lies in biology. Semaglutide activates only the GLP-1 receptor. Tirzepatide activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

Both GLP-1 and GIP are "incretin" hormones — released by your gut after eating. They signal the brain that you're full, slow stomach emptying, and regulate insulin. By activating both pathways simultaneously, tirzepatide produces a stronger overall effect on appetite reduction and metabolic regulation.

Think of it as having two keys instead of one. Semaglutide uses one key (GLP-1) to unlock appetite suppression. Tirzepatide uses two keys (GIP + GLP-1), which appears to unlock the door wider.

Side effects comparison

Both drugs share similar gastrointestinal side effects, which are the most commonly reported:

Interestingly, the data suggests tirzepatide may actually have lower rates of nausea and vomiting than semaglutide, despite producing more weight loss. This could be because the GIP receptor activation partially offsets the nausea-inducing effects of GLP-1 stimulation — though more research is needed to confirm this.

Both medications carry similar serious warnings: pancreatitis, gallbladder problems, and thyroid tumor risk (from animal studies). For a detailed timeline of what to expect, see our GLP-1 side effects guide.

Cost and availability

Without insurance, both are expensive and in a similar range:

• Mounjaro/Zepbound (tirzepatide): approximately $1,000-1,100/month
• Ozempic/Wegovy (semaglutide): approximately $900-1,350/month

Insurance coverage for the weight loss versions (Zepbound and Wegovy) is expanding but inconsistent. Both manufacturers offer savings programs for commercially insured patients.

For patients paying out of pocket, compounded semaglutide is widely available through telehealth providers at $129-300/month. Compounded tirzepatide is newer to the market and generally more expensive than compounded semaglutide. For the most up-to-date pricing, see our complete price comparison.

Which should you choose?

Tirzepatide (Mounjaro/Zepbound) might be better if:

• Maximizing weight loss is your top priority
• You haven't responded adequately to semaglutide
• You have type 2 diabetes (it has strong blood sugar benefits)
• You're sensitive to nausea (it may be better tolerated)

Semaglutide (Ozempic/Wegovy) might be better if:

• Cost is a major factor (compounded semaglutide is cheaper and more widely available)
• You want the longest track record of safety data (approved earlier)
• Your insurance covers it and not tirzepatide
• You're already responding well to it

Ultimately, both are highly effective medications that produce clinically meaningful weight loss far beyond what diet and exercise alone typically achieve. The "best" choice is the one you can access, afford, and tolerate. Talk to your healthcare provider about which fits your specific medical profile.

Frequently asked questions

Sources and clinical references